Aurinia Pharmaceuticals Inc.

NasdaqGM AUPH

Aurinia Pharmaceuticals Inc. Share Price on January 14, 2025: USD 7.55

Aurinia Pharmaceuticals Inc. Share Price is USD 7.55 on January 14, 2025, a -3.21% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Aurinia Pharmaceuticals Inc. 52-week high Share Price is USD 10.44 on December 10, 2024, which is 38.28% above the current Share Price.
Aurinia Pharmaceuticals Inc. 52-week low Share Price is USD 4.81 on April 18, 2024, which is -36.29% below the current Share Price.
Aurinia Pharmaceuticals Inc. average Share Price for the last 52 weeks is USD 6.59.

Key data

Date	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)

NasdaqGM: AUPH

Aurinia Pharmaceuticals Inc.

CEO	Mr. Peter S. Greenleaf M.B.A.
IPO Date	Sept. 3, 2014
Location	Canada
Headquarters	4464 Markham Street
Employees	300
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Key trends

Past 5 years